Science and Technology

Author Archive | xchem-editor

February 15, 2017

X-Chem Expands Collaboration with Janssen in Inflammatory Diseases

WALTHAM, Mass. – February 15, 2017 – X-Chem, Inc. (X-Chem) announced today that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties’ existing discovery and license partnership, […]

Continue Reading
January 5, 2017

Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-encoded chemical library.

2017 Jan. 5|Chembiochem.|Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-encoded chemical library. We have identified and characterized novel potent inhibitors of Bruton’s tyrosine kinase (BTK) from a single DNA encoded library of over 110 million compounds using multiple parallel selection conditions…Analysis of the co-crystal structure of […]

Continue Reading
December 20, 2016

X-Chem Announces Multi-Target Drug Discovery Collaboration with Taiho Pharmaceutical using DEX™ Technology

WALTHAM, Mass. – December 20, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced that it entered into a multi-target drug discovery collaboration with Taiho Pharmaceutical Co. Ltd. This collaboration will grant Taiho access to X-Chem’s DEX™ […]

Continue Reading
December 9, 2016

DNA-encoded chemistry: enabling the deeper sampling of chemical space.

Dec 9, 2016|Nat Rev Drug Discov.|DNA-encoded chemistry: enabling the deeper sampling of chemical space. DNA-encoded chemical library technologies are increasingly being adopted in drug discovery for hit and lead generation…This Review provides an overview of the development and applications of DNA-encoded chemistry, highlighting the challenges and future directions for the use of this technology. [Read […]

Continue Reading
November 18, 2016

Discovery of cofactor-specific, bactericidal Mycobacterium tuberculosis InhA inhibitors using DNA-encoded library technology.

Nov. 18, 2016|Proc Natl Acad Sci U S A.|Discovery of cofactor-specific, bactericidal Mycobacterium tuberculosis InhA inhibitors using DNA-encoded library technology. Millions of individuals are infected with and die from tuberculosis (TB) each year, and multidrug-resistant (MDR) strains of TB are increasingly prevalent…We describe here the use of DNA-encoded X-Chem (DEX) screening, combined with selection of […]

Continue Reading
July 26, 2016

X-Chem and AbbVie Enter into Multi-Target Drug Discovery Partnership

WALTHAM, Mass. – July 26, 2016 – X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, today announced a multi-target drug discovery agreement with AbbVie. The collaboration is focused on the discovery and development of novel treatments for diseases in oncology and immunology. […]

Continue Reading
July 12, 2016

X-Chem and Bayer Expand Drug Discovery Collaboration to Discover Novel Medicines

WALTHAM, Mass. – July 12, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, and Bayer have entered into an expanded global drug discovery collaboration across multiple therapeutic areas and target classes. The new agreement extends Bayer’s access to […]

Continue Reading
April 27, 2016

X-Chem Announces Achievement of Milestone in Alexion Collaboration

WALTHAM, Mass. – April 27 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company utilizing its industry-leading DNA-Encoded X-Chem (DEX™) drug discovery platform for the identification of first-in-class small molecule therapeutics, today announced that it has achieved a milestone in its drug discovery collaboration with Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), triggering a payment to […]

Continue Reading
March 30, 2016

X-Chem Announces License with Janssen for Protein:Protein Inhibitor Program in Inflammatory Disease

WALTHAM, Mass. – March 30, 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-Encoded X-Chem (DEX™) drug discovery platform to generate novel therapeutics, today announced that a licensing option with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has been exercised for a protein inhibitor […]

Continue Reading